Ignacio Melero

54.2k citations
467 papers · 43.3k · 24 hit papers · h-index 100

Impact in

  • Oncology top 0.02%
    • Cancer Immunotherapy and Biomarkers
  • Hepatology top 0.05%
    • Hepatocellular Carcinoma Treatment and Prognosis

Papers in

    • Cancer Immunotherapy and Biomarkers 217
    • Immunotherapy and Immune Responses 154
    • Immune Cell Function and Interaction 29
    • T-cell and B-cell Immunology 28
    • Immune cells in cancer 12

Ignacio Melero

448 papers receiving 42.4k citations

Ignacio Melero's Hit Papers

Cross-priming in cancer immunology and immunotherapy 2025 · 68 citations
680+2+4Years since publication5001k1.5k2k

Peers

Ignacio Melero
Comparison fields: 5 of 148
  • Oncology 18.4k
  • Hepatology 7k
  • Immunology 13k
  • Cancer Research 1.5k
  • Genetics 876
Replace Elizabeth M. Jaffee with:
Elizabeth M. Jaffee United States
Yang‐Xin Fu United States
Lieping Chen United States
Weiping Zou United States
Gordon James Freeman United States
Padmanee Sharma United States
James Patrick Allison United States
Alan J. Korman United States
Dmitry I. Gabrilovich United States
Robert H. Vonderheide United States
Ignacio Melero relative to Elizabeth M. Jaffee United States Elizabeth M. Jaffee's profile →
Citations per field
00.5×2×4×6.8×
Elizabeth M. Jaffee · 1×
Citations per year

Countries citing papers authored by Ignacio Melero

Since Specialization
Citations

This map shows the geographic impact of Ignacio Melero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Melero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Melero more than expected).

Fields of papers citing papers by Ignacio Melero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ignacio Melero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Melero. The network helps show where Ignacio Melero may publish in the future.

Co-authors

The 25 scholars most cited alongside Ignacio Melero, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ignacio Melero Line = papers co-authored together Ignacio Melero links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 467 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Hit paper breakdown →
20173584
2
Dendritic cells in cancer immunology and immunotherapy
Hit paper breakdown →
20192086
3
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
Hit paper breakdown →
20201068
4
Advances in immunotherapy for hepatocellular carcinoma
Hit paper breakdown →
20211008
5
Cytokines in clinical cancer immunotherapy
Hit paper breakdown →
2018979
6
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Hit paper breakdown →
2021890
7
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Hit paper breakdown →
2013841
8
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Hit paper breakdown →
2022821
9
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Hit paper breakdown →
1997797
10
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Hit paper breakdown →
2018730
11
Therapeutic vaccines for cancer: an overview of clinical trials
Hit paper breakdown →
2014668
12
Cancer vaccines: the next immunotherapy frontier
Hit paper breakdown →
2022657
13
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Hit paper breakdown →
2020648
14
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Hit paper breakdown →
2017625
15
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Hit paper breakdown →
2015564
16
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Hit paper breakdown →
2019540
17 2007532
18
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Hit paper breakdown →
2019522
19
Immunological landscape and immunotherapy of hepatocellular carcinoma
Hit paper breakdown →
2015500
20
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Hit paper breakdown →
2020434

About Ignacio Melero

Ignacio Melero is a scholar working on Oncology, Immunology, Hepatology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 467 papers that have together received 43.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (217 papers), Immunotherapy and Immune Responses (154 papers), Immune Cell Function and Interaction (29 papers), T-cell and B-cell Immunology (28 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Monoclonal and Polyclonal Antibodies Research (28 papers), Virus-based gene therapy research (28 papers) and Immune cells in cancer (12 papers). The work is most often cited by research in Oncology (18.4k citations), Hepatology (7k citations), Immunology (13k citations), Cancer Research (1.5k citations) and Genetics (876 citations). Ignacio Melero has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Jose Luis Perez-Gracia, Miguel F. Sanmamed, Maria Esperanza Rodriguez-Ruiz, Bruno Sangro, Sandra Hervás‐Stubbs, Jesús Prìeto, David Sancho, Lieping Chen, Pedro Berraondo and Francisco J. Cueto. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, OncoImmunology and Cancer Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact